Research Systems, a wholly owned subsidiary of Eastman Kodak, will provide a new, free IDL distribution platform with the upcoming release of IDL 6.0, scheduled for July. IDL Virtual Machine (VM) is designed to provide a simple, no-cost method for IDL
Research Systems, a wholly owned subsidiary of Eastman Kodak, will provide a new, free IDL distribution platform with the upcoming release of IDL 6.0, scheduled for July. IDL Virtual Machine (VM) is designed to provide a simple, no-cost method for IDL users and software developers to distribute and share compiled IDL code. The new IDL VM will allow both novice and advanced software developers to distribute compiled IDL software code, applets, or applications without additional runtime licensing or runtime license fees. IDL VM will be included with IDL 6.0 and made available for all IDL-supported platforms, including Windows, Linux, Mac OS X, and the Unix operating systems. New features in IDL 6.0 include interactive utilities called iTools, which give IDL users the power to perform ad hoc data analysis and visualization. RSI released IDL 6.0 to beta testers in May 2003.
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.